Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$72.24 USD

72.24
3,014,315

-1.43 (-1.94%)

Updated Aug 27, 2024 03:59 PM ET

After-Market: $72.22 -0.02 (-0.03%) 6:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Veeva Systems (VEEV) Gains From Solid Results for Fiscal Q4

by Zacks Equity Research

Veeva Systems' (VEEV) broad spectrum of products include Veeva Vault, Veeva CRM, Veeva Network and Veeva OpenData.

Varian & Tata Trust Tie Up to Boost Radiotherapy in India

by Zacks Equity Research

Varian's (VAR) three-year deal with Tata Trust is likely to fortify its foothold in the Asia-Pacific radiotherapy space.

The Zacks Analyst Blog Highlights: Jazz Pharmaceuticals, Lululemon Athletica, ABIOMED and DexCom

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Jazz Pharmaceuticals, Lululemon Athletica, ABIOMED and DexCom

Tirthankar Chakraborty headshot

The Best And Worst Stocks of the 10-Year Bull Market

by Tirthankar Chakraborty

We highlight some of the best and worst stocks over the bull market's 10 years.

HOLX vs DXCM: Which MedTech Stock is a Better Investment Pick?

by Zacks Equity Research

DexCom (DXCM) looks stronger than Hologic (HOLX) when it comes to current-year earnings and revenue projections as well as fundamentals.

Align Technology-Benco Dental Deal to Expand iTero Reach

by Zacks Equity Research

Align Technology (ALGN) adopts initiatives to boost top-line contributions from iTero Intraoral scanners.

GNC Holdings to Expand Portfolio With Alani Nutrition Deal

by Zacks Equity Research

With Alani Nutrition being a women-focused supplement brand, it is believed that the partnership might help GNC Holdings (GNC) widen its customer base.

Tandem's Global Growth a Boost, Operating Losses a Bane

by Zacks Equity Research

Tandem's (TNDM) t:slim X2 Insulin Pump clinching a commercial license in Canada during Q4 is a tailwind.

GNC Forms Joint Venture With IVC to Improve Cost Efficiency

by Zacks Equity Research

The joint venture is set to manufacture the products produced by GNC Holdings' (GNC) Nutra manufacturing facility.

Here's Why You Must Add Hologic (HOLX) to Your Portfolio Now

by Zacks Equity Research

Hologic's (HOLX) management is impressed with continued growth in the core Molecular Diagnostics sub-segment.

Hologic (HOLX) Receives Global Nods for Omni Hysteroscope

by Zacks Equity Research

Hologic's (HOLX) receipt of approvals for Omni Hysteroscope in Canada and Europe is expected to boost the GYN Surgical arm.

Here's Why You Should Snap Up Abbott (ABT) Stock Right Now

by Zacks Equity Research

Synergies from Alere consolidation in the form of revenues from Abbott's (ABT) Rapid Diagnostics business have been driving growth.

Here's Why You Should Invest in Chemed (CHE) Stock Right Now

by Zacks Equity Research

Chemed (CHE) sees revenue growth across its wholly-owned subsidiaries, VITAS Healthcare and Roto-Rooter. Its capital deployment policy is based on buyouts and solid return of cash to shareholders.

DexCom (DXCM) Gets Health Canada Approval for G6 CGM System

by Zacks Equity Research

DexCom's (DXCM) G6 CGM system intends to serve diabetes patients of all age groups in Canada.

Chemed Gains Ground on Solid VITAS & Roto-Rooter Businesses

by Zacks Equity Research

Chemed (CHE) witnesses solid revenue growth across key subsidiaries.

Here's Why Investors Should Buy DexCom (DXCM) Stock Now

by Zacks Equity Research

Solid growth at the Sensor, Transmitter and Receiver segments provide DexCom (DXCM) a competitive edge in the MedTech space.

DexCom's (DXCM) Q4 Earnings Beat, International Revenues Up

by Zacks Equity Research

DexCom's (DXCM) fourth-quarter 2018 results benefit from strong contributions from the Sensor, Transmitter and Receiver segments.

Here's Why You Should Invest in Illumina (ILMN) Stock Now

by Zacks Equity Research

Illumina (ILMN) continues to gain on solid international business.

DexCom (DXCM) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

DexCom (DXCM) delivered earnings and revenue surprises of 237.50% and 2.18%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Masimo and Saudi Arabia MOH Collaborate for CCHD Screening

by Zacks Equity Research

Studies have shown that Masimo's (MASI) SET pulse oximetry can improve CCHD screening, helping to save newborns.

Luminex Hurt By Segmental Sluggishness, Stiff Competition

by Zacks Equity Research

Luminex's (LMNX) dependence on its partners for revenue generation is a major problem.

DexCom (DXCM) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why Investors Should Buy CONMED (CNMD) Stock Now

by Zacks Equity Research

CONMED's (CNMD) guidance for 2019 buoys optimism in the stock.

DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom (DXCM) expects to gain from strong demand for the G6 sensors. These sensors are likely to rake in huge profits during the fourth quarter of 2018.

Ecolab (ECL) Reports Preliminary Q4 Results, Issues Guidance

by Zacks Equity Research

Ecolab (ECL) plans to spin off Upstream Energy sub-unit as a stand-alone publicly-traded company by mid-2020.